Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Events>This Event
  Events - September 2012


Next-Generation Sequencing

17 Sep 2012 - 18 Sep 2012 - London, United Kingdom



Bookmark and Share


Since its introduction in 2005 next-generation sequencing (NGS) has fundamentally altered genomics research.  Large knowledge-gaining experiments are in progress that were financially unjustifiable or even  impossible five years ago.  These include metagenomics to compare different disease states or patient variablility, genome sequencing of model and pathogenic species or ELT compound library screening techniques.

NGS is now successfully utilised by biopharmaceutical companies from the earliest stages of drug discovery to provide detailed genomic data and clinical applications are now emerging.  These range from investigating the molecular basis of drug resistance and planning antimicrobial regimens, to vaccine development and disease diagnostics.  In the rapidly growing field of personalised medicine, eight percent of medicines now have a biomarker or stratified element as compared to just a few percent five years ago.

As sequencing costs continue to fall, the future will see even faster identification of responders and non-responders, benefiting patients, prescribers and payors.

Why should you attend this event? Join us for two days of insights and case studies from leading experts and industry executives, enabling you to:

    * Generate longer nucleic acid and oligonucleotide sequences of higher quality
    * Increase consensus accuracy and genome coverage
    * Maximise the alignment and assembly of NGS reads with reference sequences
    * Enhance signal-to-noise measurements in real-time sequencing
    * Utilise exomics to elucidate gene families implicated in disease or pharmacogenetic effects
    * Improve mapping in repetitive regions when resequencing
    * Catalogue the transcriptomes of cells, tissues and pathogens
    * Perform quantitative applications more effectively with third generation platforms
    * Clarify analysis requirements prior to epigenomic studies



Further information
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!